These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 27787906

  • 1. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
    Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmeström C, Piehl F, Olsson T, Lycke J.
    J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study.
    Kızılay T, Akbayir E, Erol R, Demir AS, Özkan Yaşargün D, Yilmaz V, Tuzun E, Turkoglu R.
    Eur Neurol; 2024 Apr; 87(4):203-210. PubMed ID: 38754397
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T, Hatzifilippou E, Arnaoutoglou M, Balogiannis S, Koutsouraki E.
    Hell J Nucl Med; 2019 Apr; 22 Suppl 2():113-121. PubMed ID: 31802051
    [Abstract] [Full Text] [Related]

  • 8. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P, Losy J, Kramer L, Wójcicka M, Kaufman E.
    J Neurol Sci; 2017 Sep 15; 380():22-26. PubMed ID: 28870573
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
    de Flon P, Gunnarsson M, Laurell K, Söderström L, Birgander R, Lindqvist T, Krauss W, Dring A, Bergman J, Sundström P, Svenningsson A.
    Neurology; 2016 Jul 12; 87(2):141-7. PubMed ID: 27316241
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis.
    Hradilek P, Revendova KZ, Horakova J, Bunganic R, Pelisek O, Zeman D, Hanzlikova P, Kusnierova P.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Mar 12; 167(1):30-35. PubMed ID: 36695545
    [Abstract] [Full Text] [Related]

  • 19. Prognostic relevance of the C-X-C motif chemokine ligand 13 and interleukin-8 in predicting the transition from clinically isolated syndrome to multiple sclerosis.
    Klíčová K, Mareš J, Sobek O, Rous Z, Rous M, Raška M, Hartung HP.
    Eur J Neurosci; 2024 Jun 12; 59(11):2955-2966. PubMed ID: 38453679
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.